News for BioAtla, Inc. (BCAB)

BioAtla (BCAB) has revealed promising findings from a Phase 2 clinical trial assessing Ozuriftamab Vedotin (Oz-V) in patients with heavily pretreated squamous c

Release Date: May 06, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points BioAtla Inc (BCAB

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NBCAB.OQ - Bioatla IncQ1 2025 Bioatla Inc Earnings CallMay 06, 2025 / 08:30PM GMT =============

BioAtla (BCAB), a biotechnology company, is making significant strides with its CAB platform, particularly in a Phase 1 study focused on a bispecific T-cell eng

The following slide deck was published by BioAtla, Inc.

BioAtla, Inc. (NASDAQ:BCAB) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, Investor...

**media[616597]**

SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. ( BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally

SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. ( BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. ( BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. ( BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally

R&D Expenses: $11.6 million for Q4 2024, down from $22.7 million in Q4 2023.General and Administrative Expenses: $4.6 million for Q4 2024, down from $5.9 milli

Mar 27, 2025 / 08:30PM GMTOperator Good day, everyone, and welcome to today's BioAtla fourth quarter and fiscal year 2024 earnings call. (Operator Instructions)

BioAtla, Inc. (NASDAQ:BCAB) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, Investor...

CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026 Mecbot

CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company expects its cash and cash equivalents w

**media[572499]**

SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. ( BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally

**media[571855]**